Last checked at 18 Sep 2023 09:51
18 September 2023
Assura plc
Vesting and Sale of Restricted Shares
Assura plc ("Assura"), the leading primary care property investor and developer announces that on 15 September 2023, the restricted shares referred to below vested for the PDMR listed below.
The table below shows the number of shares vesting, the number of shares sold to satisfy income tax and national insurance liabilities, the number of shares sold and the number of shares retained following the sales. The award was satisfied from shares held by the Employee Benefit Trust and no additional shares have been listed.
Number of Shares vesting | Number of shares sold to satisfy income tax and national insurance liabilities | Additional shares sold | Number of shares after shares sold
| |
Orla Ball | 48,767 | 22,921 | 25,846 | - |
The Remuneration Committee of Assura had agreed that sufficient restricted shares may be sold to cover the arising income tax and national insurance liabilities and that Ms Ball could sell the balance of her restricted shares in full. The relevant market price for taxation purposes is £0.4612 per share.
As a result of the above, the PDMR's shareholding and those of their connected persons is as follows:
Shareholding on 14 September 2023 | Shareholding post exercise | |
Orla Ball | 21,072 | 21,072 |
The Notification of Dealing Form for the PDMRs can be found below.
This notification is made in accordance with the Market Abuse Regulation.
Notification of dealing form
1 | Details of the person discharging managerial responsibilities/person closely associated
| |||||||
a) | Name
| Orla Ball | ||||||
2 | Reason for the notification
| |||||||
a) | Position/status
| General Counsel | ||||||
b) | Initial notification/ Amendment
| Initial notification | ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||
a) | Name
| Assura plc | ||||||
b) | LEI
| 21380026T19N2Y52XF72 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 10 pence each
GB00BVGBWW93 | ||||||
b) | Nature of the transaction
|
Vesting of restricted share awards under PSP
| ||||||
c) | Price(s) and volume(s)
|
| ||||||
d) | Aggregated information
- Aggregated volume
- Price
|
N/A | ||||||
e) | Date of the transaction
| 15 September 2023 | ||||||
f) | Place of the transaction
| XLON | ||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 10 pence each
GB00BVGBWW93 | ||||||
b) | Nature of the transaction
| Sale of shares to satisfy tax and national insurance liabilities
| ||||||
c) | Price(s) and volume(s)
|
| ||||||
d) | Aggregated information
- Aggregated volume
- Price
|
| ||||||
e) | Date of the transaction
| 15 September 2023 | ||||||
f) | Place of the transaction
| XLON | ||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 10 pence each
GB00BVGBWW93 | ||||||
b) | Nature of the transaction
| Sale of shares
| ||||||
c) | Price(s) and volume(s)
|
| ||||||
d) | Aggregated information
- Aggregated volume
- Price
|
| ||||||
e) | Date of the transaction
| 15 September 2023 | ||||||
f) | Place of the transaction
| XLON | ||||||
- ENDS -
For more information, please contact:
Assura plc |
Tel: 0161 515 2043 |
David Purcell, Investor Relations Director
| Email: Investor@assura.co.uk |
FGS Global Gordon Simpson | Tel: 0207 251 3801 Email: Assura@fgsglobal.com |
Notes to Editors
Assura plc is a national healthcare premises specialist and UK REIT based in Altrincham, UK - caring for more than 600 primary healthcare buildings, from which over six million patients are served.
A constituent of the FTSE 250 and the EPRA* indices, as at 31 March 2023, Assura's portfolio was valued at £2.7 billion.
At Assura, we BUILD for health. Assura builds better spaces for people and places, invests in skills and inspires new ways of working, and unlocks the power of design and innovation to deliver lasting impact for communities - aiming for six million people to have benefitted from improvements to and through its healthcare buildings by 2026.
Assura is leading for a sustainable future, targeting net zero carbon across its portfolio by 2040.
Further information is available at www.assuraplc.com
*EPRA is a registered trademark of the European Public Real Estate Association